Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial-Reference-Cited by-同舟云学术

Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial

Published:2017-09 Issue: Volume:23 Page:79-87
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Kimura Kiminori,Ikoma Akemi,Shibakawa Maki,Shimoda Shinji,Harada Kenichi,Saio Masanao,Imamura Jun,Osawa Yosuke,Kimura Masamichi,Nishikawa Koji,Okusaka Takuji,Morita Satoshi,Inoue Kazuaki,Kanto Tatsuya,Todaka Koji,Nakanishi Yoichi,Kohara Michinori,Mizokami Masashi

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference30 articles.

1. Therapeutic potential of targeting Wnt/beta-catenin pathway in treatment of colorectal cancer: rational and progress;Bahrami;J. Cell. Biochem.,2017

2. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches;Canalis;Nat. Rev. Endocrinol.,2013

3. Convergence of Wnt signaling on the HNF4alpha-driven transcription in controlling liver zonation;Colletti;Gastroenterology,2009

4. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals;Conti;J. Hepatol.,2016

5. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis;Curry;N. Engl. J. Med.,2015

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined targeting of Hedgehog/GLI1 and Wnt/β‐catenin pathways in mantle cell lymphoma;Hematological Oncology;2024-08-29

2. Dysfunction of dendritic cells in tumor microenvironment and immunotherapy;Cancer Communications;2024-07-25

3. Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?;Pharmaceuticals;2024-07-16

4. Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV/HCV coinfection: an investigator-initiated, open-label, non-randomised, single-centre, phase I study;BMJ Open Gastroenterology;2024-04

5. Plasma extracellular vesicle microRNAs reflecting the therapeutic effect of the CBP/β-catenin inhibitor PRI-724 in patients with liver cirrhosis;Scientific Reports;2024-03-15